Literature DB >> 25028378

Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis.

Patrick H Dessein1, Linda Tsang2, Angela J Woodiwiss2, Gavin R Norton2, Ahmed Solomon2.   

Abstract

OBJECTIVE: Depending on physiological context, the adipokine chemerin can reduce or enhance cardiovascular risk. We investigated whether chemerin concentrations represent cardiovascular disease risk in rheumatoid arthritis (RA).
METHODS: We assessed ELISA-determined chemerin concentrations and those of 4 early endothelial activation molecules as well as angiopoietin 2, which mediates angiogenesis and thereby contributes to advanced atherosclerosis, the common carotid artery intima-media thickness (cIMT), and carotid artery plaque by ultrasound in 236 patients (114 black and 122 white) with RA. Relationships were identified in potential confounder and mediator-adjusted mixed regression models.
RESULTS: Mean (SD) chemerin and median (interquartile range) angiopoietin 2 concentrations were 114 (35) ng/ml and 2560 (2044-3341) pg/ml, respectively; the mean (SD) cIMT was 0.708 (0.110) mm, and 40.3% of patients had plaque. Chemerin concentrations were not related to those of early endothelial activation molecules, but associated with those of angiopoietin 2 [β SE = 0.002 (0.0004), p < 0.0001] and plaque [OR 1.006 (95% CI 1.00-1.013), p = 0.05] in all patients. The presence of major conventional cardiovascular risk factors, generalized and abdominal obesity, and RA severity markers modified the independent chemerin-cardiovascular risk relations (interaction p < 0.05). Consequently, chemerin concentrations were associated with cIMT in those with but not without overweight or generalized obesity and abdominal obesity [β SE = 0.001 (0.0003), p = 0.005 and 0.001 (0.0001), p = 0.001 vs -0.001 (0.0004), p = 0.2 and -0.0002 (0.0004), p = 0.6, respectively], and with plaque in those without but not with generalized obesity [OR 1.008 (95% CI) 1.000-1.016, p = 0.03 vs 1.003 (0.990-1.017), p = 0.6, respectively]. The β (SE) for the chemerin-intima-media thickness relations in patients with overweight or generalized obesity and abdominal obesity were larger than in those without these characteristics (p < 0.0001 and = 0.04, respectively).
CONCLUSION: Chemerin is associated with endothelial activation and atherosclerosis in RA. Adiposity influences the chemerin-atherosclerotic phenotype relations in RA.

Entities:  

Keywords:  ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHEMERIN; ENDOTHELIAL ACTIVATION; OBESITY; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2014        PMID: 25028378     DOI: 10.3899/jrheum.140122

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Omentin concentrations are independently associated with those of matrix metalloproteinase-3 in patients with mild but not severe rheumatoid arthritis.

Authors:  Chanel Robinson; Linda Tsang; Ahmed Solomon; Angela J Woodiwiss; Sule Gunter; Aletta M E Millen; Gavin R Norton; Maria J Fernandez-Lopez; Ivana Hollan; Patrick H Dessein
Journal:  Rheumatol Int       Date:  2016-07-30       Impact factor: 2.631

2.  Role of chemerin/CMKLR1 in the maintenance of early pregnancy.

Authors:  Xuezhou Yang; Junning Yao; Qipeng Wei; Jinhai Ye; Xiaofang Yin; Xiaozhen Quan; Yanli Lan; Hui Xing
Journal:  Front Med       Date:  2018-03-17       Impact factor: 4.592

3.  The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Authors:  Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

Review 4.  Chemerin: A comprehensive review elucidating the need for cardiovascular research.

Authors:  David J Ferland; Stephanie W Watts
Journal:  Pharmacol Res       Date:  2015-07-23       Impact factor: 7.658

Review 5.  Chemerin as an independent predictor of cardiovascular event risk.

Authors:  Sinan İnci; Gökhan Aksan; Pınar Doğan
Journal:  Ther Adv Endocrinol Metab       Date:  2016-02-08       Impact factor: 3.565

6.  Inverse Relationship of the CMKLR1 Relative Expression and Chemerin Serum Levels in Obesity with Dysmetabolic Phenotype and Insulin Resistance.

Authors:  Fernanda-Isadora Corona-Meraz; Rosa-Elena Navarro-Hernández; Sandra-Luz Ruíz-Quezada; Perla-Monserrat Madrigal-Ruíz; Jorge Castro-Albarrán; Efraín Chavarría-Ávila; Milton-Omar Guzmán-Ornelas; Eduardo Gómez-Bañuelos; Marcelo-Herón Petri; Joel-Isidro Ramírez-Cedano; María-Elena Aguilar-Aldrete; Clara Ríos-Ibarra; Mónica Vázquez-Del Mercado
Journal:  Mediators Inflamm       Date:  2016-04-28       Impact factor: 4.711

7.  Chemerin Stimulates Vascular Smooth Muscle Cell Proliferation and Carotid Neointimal Hyperplasia by Activating Mitogen-Activated Protein Kinase Signaling.

Authors:  Wei Xiong; Yu Luo; Lin Wu; Feng Liu; Huadong Liu; Jianghua Li; Bihong Liao; Shaohong Dong
Journal:  PLoS One       Date:  2016-10-28       Impact factor: 3.240

8.  Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Silvia Rollefstad; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Anne Grete Semb
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

9.  Circulating adipokines are associated with Kawasaki disease.

Authors:  Xin-Yan Zhang; Ting-Ting Yang; Xiu-Fen Hu; Yu Wen; Feng Fang; Hui-Ling Lu
Journal:  Pediatr Rheumatol Online J       Date:  2018-05-08       Impact factor: 3.054

10.  The Impact of Different Classification Criteria Sets on the Estimated Prevalence and Associated Risk Factors of Diastolic Dysfunction in Rheumatoid Arthritis.

Authors:  Lebogang Mokotedi; Sulé Gunter; Chanel Robinson; Gavin R Norton; Angela J Woodiwiss; Linda Tsang; Patrick H Dessein; Aletta M E Millen
Journal:  Int J Rheumatol       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.